# Neuroleptic Malignant Syndrome: Recognition and Management

## NMSIS Website/Email:

[www.nmsis.org](http://www.nmsis.org)

[info@nmsis.org](mailto:info@nmsis.org)

Ph: 607-674-7920

## References (in same order as presentation)

**Delay J et al. (1960), Ann Med Psychol 118(1):145-152**

**Caroff SN et al. (1991), Psychiatric Annals 21:130-147**

**Lazarus A et al. (1989), The Neuroleptic Malignant Syndrome and Related Conditions, Washington D.C.: American Psychiatric Publishing, Inc.**

**Spivak B et al. (2000), Eur Psychiatry 15(5):330-333;**

**Stubner S et al. (2004), Pharmacopsychiatry 37(suppl 1):S54-S64**

**HCUPnet, Agency for Health Care Research and Quality. Available at: http://hcupnet.ahrq.gov**

**Keck PE Jr et al. (1989), Arch Gen Psychiatry 46(10):914-918**

**Strawn JR et al. (2008), Current Psychiatry 7(1):95-101**

**Caroff SN et al. (2001), Am J Anesthesiology 28:387-393**

**Caroff SN, Clin Psychopharmacol Neurosci, 2020**

**Caroff SN, Mann SC (1993), Med Clin North Am 77(1):185-202**

**Velamoor VR et al. (1994), J Nerv Ment Dis 182(3):168-173**

**Caroff SN, Mann SC (1988), Psychopharmacol Bull 24(1):25-29**

**Caroff SN et al. (2000), J Clin Psychopharmacol 20(2):257-259;**

**Yamawaki et al. (1990), Hiroshima J Anesthesia 26:35-44**

**Davis JM et al. (2000), Psychiatr Annals 30:325-331**

**Strawn JR et al. (2008), Current Psychiatry 7(2):95-101**

## References continued…

**Francis et al, CNS Spectrums, 2000; Wang et al, Mov Disord, 2001**

**Davis JM et al. (2000), Psychiatr Annals 30:325-331**

**Caroff SN (2003), Current Psychiatry 2(12):36-42**

**Mann SC et al. (2000), Psychiatr Annals 30:363-374;**

**Gurrera RJ (1999), Am J Psychiatry 156(2):169-180**